News

'Compelling' update on virus with 'pandemic potential' that kills up to 85% of infected
The virus can be fatal in up to 85% of cases, initially causing symptoms such as fever, headaches, pain, vomiting and a sore ...
New update on virus with 'pandemic potential' that kills up to 85% of those it infects
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Devdiscourse6h
Potential Vision Risks Associated with Novo's Weight-Loss Drugs
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Devdiscourse14h
Health Updates: Measles in Texas and Ozempic's Eye Concern
Texas reports no new measles cases for the first time since February, maintaining 742 total cases. Meanwhile, Novo Nordisk's Ozempic is linked to rare serious eye disorders, possibly causing vision ...
India Today2d
European drugs regulator flags rare eye risk with Ozempic use
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Dermatology Advisor2d
European Atopic Eczema Guidelines Update Includes New, Expanded Drug Approvals
The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib and abrocitinib.
Morningstar3d
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory ...